Back

Fennec reports 24% hearing loss in Japan PEDMARK study

Verifying
  • Fennec reported Phase 2 STS-J01 results for PEDMARK in Japanese pediatric cancer patients.
  • 24.0% of 25 primary-efficacy patients had ASHA-defined hearing loss versus 56.4% historically.
  • STS-J01 enrolled 33 patients across 11 Japanese institutions and administered PEDMARK six hours after cisplatin.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.